SOURCE-LINKED STUDY SUMMARY
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Abstract summarizedQuality not appraised
- What was studied
- A post-hoc pooled participant-level analysis combined four randomized placebo-controlled semaglutide trials to examine heart-failure events.
- Who / model studied
- The analysis included people with investigator-reported HFpEF drawn from trials enrolling obesity-related HFpEF, cardiovascular disease with overweight or obesity, or diabetes with chronic kidney disease.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Semaglutide reduced the combined risk of cardiovascular death or worsening heart failure and reduced worsening heart-failure events alone; cardiovascular death alone was not significantly reduced.
- Limitations & context
- This was a post-hoc pooled analysis across trials with different entry populations and semaglutide doses.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(24)01643-x